Target | Inactivating treatment | Organ/ tissue | Subregion | Age, months | Recovery half-life | Reference |
---|---|---|---|---|---|---|
Dopamine D1 receptor | EEDQ | Brain | Striatum | 4 | 3.5 d (84 h) | (Battaglia et al., 1988) |
EEDQ | Brain | Striatum | 4 | 3.1-3.3 d (74-80 h) | (Giorgi et al., 1991) | |
EEDQ | Brain | Striatum | 23 | 6.1 d (146 h) | (Giorgi et al., 1992) | |
EEDQ | Brain | Striatum | 28 | 5.8 d (138 h) | (Battaglia et al., 1988) | |
EEDQ | Brain | N. accumbens | 4 | 2.7 d (64 h) | (Giorgi et al., 1991; Giorgi et al., 1992) | |
EEDQ | Brain | N. accumbens | 23 | 4.5 d (108 h) | (Giorgi et al., 1992) | |
EEDQ | Brain | Subst. nigra | 4 | 7.6-8.3 d (182-200 h) | (Giorgi et al., 1991) | |
EEDQ | Brain | Subst. nigra | 23 | 9.6 d (230 h) | (Giorgi et al., 1992) | |
EEDQ | Eye | Retina | 4 | 2.2-2.3 d (53-56 h) | (Giorgi et al., 1991) | |
EEDQ | Eye | Retina | 23 | 2.9 d (70 h) | (Giorgi et al., 1992) | |
Dopamine D2 receptor | EEDQ | Brain | Striatum | 1 | 1.9 d (45 h) | (Leff et al., 1984) |
EEDQ | Brain | Striatum | 4 | 3.3 d (79 h) | (Norman et al., 1987) | |
EEDQ | Brain | Striatum | 9 | 5.0 d (120 h) | (Norman et al., 1987) | |
EEDQ | Brain | Striatum | 9-12 | 5.0 d (119 h) | (Leff et al., 1984) | |
EEDQ | Brain | Striatum | 28 | 5.7 d (136 h) | (Norman et al., 1987) | |
Alpha1-adrenoceptor | PBZ | Brain | Cortex | 3 | 7 d (168 h) | (Zhou et al., 1984) |
PBZ | Brain | Cortex | 24 | 14 d (336 h) | (Zhou et al., 1984) | |
PBZ | Brain | Hypothalamus | 3 | 8 d (192 h) | (Zhou et al., 1984) | |
PBZ | Brain | Hypothalamus | 24 | 15 d (360 h) | (Zhou et al., 1984) | |
Alpha2-adrenoceptor | PBZ | Brain | Cortex | 3 | 5 d (120 h) | (Zhou et al., 1984) |
PBZ | Brain | Cortex | 24 | 20 d (480 h) | (Zhou et al., 1984) | |
Beta1-adrenoceptor | BAAM | Heart | — | 1-2 | approximately 3.8 d (approximately 90 h)* | (Baker and Pitha, 1982; Pitha et al., 1982) |
BAAM | Heart | — | 28 | approximately 13.3 d (approximately 320 h)* | (Baker and Pitha, 1982; Pitha et al., 1982) | |
Beta2-adrenoceptor | BAAM | Lung | — | 1-2 | approximately 10 d (approximately 250 h)* | (Baker and Pitha, 1982; Pitha et al., 1982) |
BAAM | Lung | — | 28 | approximately 16.7 d (approximately 400 h)* | (Baker and Pitha, 1982; Pitha et al., 1982) | |
5-HT1A receptor | EEDQ | Brain | Hippocampus | 3 | 6.3 d (151 h) | (Keck and Lakoski, 2000) |
EEDQ | Brain | Hippocampus | approximately 6–12 | 1.8 d (43 h) | (Keck and Lakoski, 1996a) | |
EEDQ | Brain | Hippocampus | 22 | 2.2 d (53 h) | (Keck and Lakoski, 2000) | |
EEDQ | Brain | Cortex | approximately 6–12 | 7.7 d (185 h) | (Keck and Lakoski, 1996a) | |
5-HT2 receptor | EEDQ | Brain | Cortex | 4 | 1.9 d (45 h) | (Battaglia et al., 1987) |
EEDQ | Brain | Cortex | 28 | 4.1 d (98 h) | (Battaglia et al., 1987) | |
GABAA receptor/Bz site | EEDQ | Brain | Cortex | 2 | 1.1 d (25 h) | (Miller et al., 1991a) |
EEDQ | Brain | Cortex | 20 | 3.1 d (75 h) | (Miller et al., 1991a) |
PBZ, phenoxybenzamine.
*Estimated from data in Baker and Pitha (1982) and Pitha et al. (1982).